Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "JLP-2302" and "JP-1366" in Healthy Volunteers
Latest Information Update: 29 Sep 2025
At a glance
- Drugs JLP 2302 (Primary) ; Zastaprazan (Primary)
- Indications Erosive oesophagitis; Gastric cancer; Peptic ulcer
- Focus Pharmacokinetics
- Sponsors Onconic Therapeutics
Most Recent Events
- 29 Sep 2025 New trial record